Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions for the treatment of Alzheimer's disease

A mixture, technology of use, applied in the direction of drug combination, application, food science, etc., can solve the problems shown to prevent, prevent or reverse, and not show the change of disease etiology

Inactive Publication Date: 2011-12-07
CONCOURSE HEALTH SCI
View PDF6 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the extent to which anticholinesterase inhibitors and memantine affect AD produced only a temporary effect on AD symptoms and did not appear to alter the etiology of the disease
It is believed that no treatment in use today has been shown to prevent, halt or reverse this neurodegenerative process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions for the treatment of Alzheimer's disease
  • Compositions for the treatment of Alzheimer's disease
  • Compositions for the treatment of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] Example 1: Evaluation of Therapy in Tg2576 Mice

Embodiment 1a

[0118] Example 1a: Cognitive Assessment

[0119] We reasoned that a combination therapy comprising multiple antioxidants and vitamins would appear to be most effective in the treatment of human AD. To support this inference, we tested the following nutrient combinations in two well-established and used AD mouse models:

[0120] Table 4: Concentrations of Joint Mixture Components vs. Low and High Concentration Diets Added to AIN-17 Rodent Diets

[0121]

[0122] As noted above, the high strength diet and low strength diet combination mixtures were prepared to provide about 660 and about 220 mg combination mixture per 1 kg rodent diet, respectively. Green Tea Extract, Bioperine with folic acid and B vitamins 12 The sources provide the respective active ingredient percentages separately. Green tea provides 50% EGCG; Bioperine Provides 98% piperine; folic acid source provides 10% folic acid; and vitamin B 12 Source Provides 1% B Vitamins 12 . Factoring these percentag...

Embodiment 2

[0131] Example 2: Evaluation of Therapy in 3xTg-AD Mice

[0132] Given these extremely promising results, we attempted to validate a diet containing the combination mixture by testing a high-concentration diet in a second AD mouse model (3xTg-AD mouse model). 3xTg-AD mice progressively develop Aβ and tauopathies with time- and region-specific features that closely mimic their occurrence in human AD brains. Despite equal expression of human APP and human tau transgenes, Aβ deposition precedes tangle lesions. Extracellular Aβ deposits manifested in the cortex by 6 months of age, and by 12 months, Thioflavin S-positive and Congo red-positive. At ~6 months of age, tau translocates to the dendritic compartment of the cell body, reactivity with conformation-specific antibodies (such as the mouse monoclonal antibody MC-1) is evident by 10 months, and shortly thereafter at approximately 10 months. Immunoreactivity for phospho-specific tau markers was evident at -12 months of age. T...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Preparations for the prevention and treatment of neurological disorders and cognitive deficits, i.e. Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, mild cognitive impairment and other types of dementia, comprising a therapeutically effective amount curcumin, piperine, epigallocatechin-3-gallate (EGCG), and one of N-acetylcysteine, benfotiamine, and alpha-lipoic acid or more. This association points to some or all of the pathways that can lead to nervous system deficits, degeneration and disease.

Description

technical field [0001] The present invention relates to novel agents for reducing the phosphorylation of tau protein or the presence of β-amyloid plaques, thereby preventing and treating cognitive and neurological diseases, such as Alzheimer's Disease (AD). Other neurological diseases that may be treated in accordance with the present invention include amyotrophic lateral sclerosis; mild cognitive impairment; frontotemporal dementia, such as that associated with chromosome 17-linked Parkinson's neurological dysfunction; frontotemporal lobar degeneration, also known as Pick's disease; progressive supranuclear palsy; encephalomyelitis; multiple sclerosis; or corticobasal degeneration; Parkinson's disease; and other types of dementia. The formulation comprises, for example, a therapeutically effective amount of the following combination: curcumin, piperine, epigallocatechin-3-gallate (EGCG), and N-acetylcysteine, phenyl One or more of benfotiamine and α-lipoic acid. This associ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A23L1/00A61K31/12A61K31/195A61K31/353A61K31/385A61K31/675A61K36/67
CPCA61K31/4453A61K31/12A61K31/4525A61K36/67A61K9/06A61K31/353A61K31/198A61P25/28A61K2300/00
Inventor 库尔特·亨德里克斯
Owner CONCOURSE HEALTH SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com